Please enable JavaScript to continue using this application.

Compare $KURA vs $RIGL | Chartloom

Compare

$KURA vs $RIGL

Kura Oncology Inc · Rigel Pharmaceuticals Inc

KURA

Kura Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Compare $KURA vs $RIGL

Comparing Kura Oncology Inc and Rigel Pharmaceuticals Inc

KURAKura Oncology Inc

RIGLRigel Pharmaceuticals Inc

KURAKura Oncology Inc

Market cap

$941M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.49x

Rev growth (TTM)

-7.3%

YTD performance

2.6%

52W performance

5.2%

FCF yield

-12.5%

RIGLRigel Pharmaceuticals Inc

Market cap

$908M

P/E (TTM)

2.98x

Forward P/E (NTM)

15.85x

Forward P/S (NTM)

2.61x

Rev growth (TTM)

3.3%

YTD performance

17.3%

52W performance

70.7%

FCF yield

1.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KURA

RIGL

Detailed metrics comparison

KURA

Kura Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

KURA$941M

RIGL$908M

Enterprise Value

KURA$881M

RIGL$886M

Price

KURA$10.60

RIGL$49.08

P/E Ratio

KURAN/A

RIGL2.98x

P/S Ratio

KURA12.18x

RIGL3.28x

EV/Sales

KURA11.40x

RIGL3.20x

EV/EBITDA

KURA0.00x

RIGL9.50x

P/B Ratio

KURA19.56x

RIGL2.07x

P/FCF Ratio

KURAN/A

RIGL100.69x

EV/FCF

KURA-7.50x

RIGL98.29x

PEG Ratio

KURAN/A

RIGL0.01x

Forward P/E (NTM)

KURAN/A

RIGL15.85x

Forward P/S (NTM)

KURA6.49x

RIGL2.61x

Revenue (TTM)

KURA$77M

RIGL$277M

Revenue Growth (YoY)

KURA-7.3%

RIGL3.3%

Forward Rev Growth

KURA106.3%

RIGL21.9%

Gross Margin (TTM)

KURA72.4%

RIGL91.4%

Operating Margin (TTM)

KURA0.0%

RIGL31.4%

EBITDA Margin (TTM)

KURA-410.2%

RIGL32.4%

Net Margin (TTM)

KURA-384.3%

RIGL116.3%

FCF Margin (TTM)

KURA-152.1%

RIGL3.3%

Net Income (TTM)

KURA$-297M

RIGL$322M

FCF (TTM)

KURA$-117M

RIGL$9M

EPS (TTM)

KURA-$3.34

RIGL$16.45

ROE (TTM)

KURA-20718.0%

RIGL96.5%

ROA (TTM)

KURA-4517.0%

RIGL72.3%

ROIC (TTM)

KURA-19400.0%

RIGL84.1%

Cash

KURA$70M

RIGL$61M

Debt

KURA$10M

RIGL$39M

Net Cash/Debt

KURA$60M

RIGL$22M

Current Ratio (TTM)

KURA4.73x

RIGL1.94x

Quick Ratio (TTM)

KURA4.47x

RIGL1.58x

Debt/Equity (TTM)

KURA0.20x

RIGL0.09x

Debt/Assets (TTM)

KURA0.0%

RIGL0.0%

Interest Coverage (TTM)

KURAN/A

RIGLN/A

Net Debt/EBITDA (TTM)

KURA0.00x

RIGL0.00x

Beta

KURA0.53

RIGL1.26

52W Performance

KURA5.2%

RIGL70.7%

YTD Performance

KURA2.6%

RIGL17.3%

% from 52W High

KURA-23.7%

RIGL-6.0%

% from 52W Low

KURA44.1%

RIGL96.7%

Asset Turnover (TTM)

KURA0.12x

RIGL0.62x

FCF Yield (TTM)

KURA-12.5%

RIGL1.0%

Earnings Yield (TTM)

KURA-31.5%

RIGL35.5%

Dividend Yield (TTM)

KURAN/A

RIGLN/A

Rule of 40

KURA-159.3

RIGL6.6

EV/GP/RG

KURA0.09

RIGL0.13

Ticker research

View KURA research View RIGL research

Metric	KURA Kura Oncology Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$941M	$908M
Enterprise Value	$881M	$886M
Price	$10.60	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	12.18x	3.28x
EV/Sales	11.40x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	19.56x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-7.50x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	6.49x	2.61x
Revenue & Growth
Revenue (TTM)	$77M	$277M
Revenue Growth (YoY)	-7.3%	3.3%
Forward Rev Growth	106.3%	21.9%
Profitability
Gross Margin (TTM)	72.4%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-410.2%	32.4%
Net Margin (TTM)	-384.3%	116.3%
FCF Margin (TTM)	-152.1%	3.3%
Net Income (TTM)	$-297M	$322M
FCF (TTM)	$-117M	$9M
EPS (TTM)	-$3.34	$16.45
ROE (TTM)	-20718.0%	96.5%
ROA (TTM)	-4517.0%	72.3%
ROIC (TTM)	-19400.0%	84.1%
Financial Health
Cash	$70M	$61M
Debt	$10M	$39M
Net Cash/Debt	$60M	$22M
Current Ratio (TTM)	4.73x	1.94x
Quick Ratio (TTM)	4.47x	1.58x
Debt/Equity (TTM)	0.20x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.53	1.26
52W Performance	5.2%	70.7%
YTD Performance	2.6%	17.3%
% from 52W High	-23.7%	-6.0%
% from 52W Low	44.1%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.12x	0.62x
FCF Yield (TTM)	-12.5%	1.0%
Earnings Yield (TTM)	-31.5%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-159.3	6.6
EV/GP/RG	0.09	0.13
Ticker research	View KURA research	View RIGL research

Valuation

P/E Ratio

RIGL

2.98x

P/S Ratio

RIGL

3.28x

KURA

12.18x

EV/FCF

KURA

-7.50x

RIGL

98.29x

Growth & revenue

Revenue Growth TTM

RIGL

3.3%

KURA

-7.3%

Forward Revenue Growth

KURA

106.3%

RIGL

21.9%

Profitability & performance

Gross Margin

RIGL

91.4%

KURA

72.4%

ROE

RIGL

96.5%

KURA

-20718.0%

FCF Yield %

RIGL

1.0%

KURA

-12.5%

52-Week Performance

RIGL

70.7%

KURA

5.2%

Detailed metrics comparison

KURA

Kura Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

KURA$941M

RIGL$908M

Enterprise Value

KURA$881M

RIGL$886M

Price

KURA$10.60

RIGL$49.08

P/E Ratio

KURAN/A

RIGL2.98x

P/S Ratio

KURA12.18x

RIGL3.28x

EV/Sales

KURA11.40x

RIGL3.20x

EV/EBITDA

KURA0.00x

RIGL9.50x

P/B Ratio

KURA19.56x

RIGL2.07x

P/FCF Ratio

KURAN/A

RIGL100.69x

EV/FCF

KURA-7.50x

RIGL98.29x

PEG Ratio

KURAN/A

RIGL0.01x

Forward P/E (NTM)

KURAN/A

RIGL15.85x

Forward P/S (NTM)

KURA6.49x

RIGL2.61x

Revenue (TTM)

KURA$77M

RIGL$277M

Revenue Growth (YoY)

KURA-7.3%

RIGL3.3%

Forward Rev Growth

KURA106.3%

RIGL21.9%

Gross Margin (TTM)

KURA72.4%

RIGL91.4%

Operating Margin (TTM)

KURA0.0%

RIGL31.4%

EBITDA Margin (TTM)

KURA-410.2%

RIGL32.4%

Net Margin (TTM)

KURA-384.3%

RIGL116.3%

FCF Margin (TTM)

KURA-152.1%

RIGL3.3%

Net Income (TTM)

KURA$-297M

RIGL$322M

FCF (TTM)

KURA$-117M

RIGL$9M

EPS (TTM)

KURA-$3.34

RIGL$16.45

ROE (TTM)

KURA-20718.0%

RIGL96.5%

ROA (TTM)

KURA-4517.0%

RIGL72.3%

ROIC (TTM)

KURA-19400.0%

RIGL84.1%

Cash

KURA$70M

RIGL$61M

Debt

KURA$10M

RIGL$39M

Net Cash/Debt

KURA$60M

RIGL$22M

Current Ratio (TTM)

KURA4.73x

RIGL1.94x

Quick Ratio (TTM)

KURA4.47x

RIGL1.58x

Debt/Equity (TTM)

KURA0.20x

RIGL0.09x

Debt/Assets (TTM)

KURA0.0%

RIGL0.0%

Interest Coverage (TTM)

KURAN/A

RIGLN/A

Net Debt/EBITDA (TTM)

KURA0.00x

RIGL0.00x

Beta

KURA0.53

RIGL1.26

52W Performance

KURA5.2%

RIGL70.7%

YTD Performance

KURA2.6%

RIGL17.3%

% from 52W High

KURA-23.7%

RIGL-6.0%

% from 52W Low

KURA44.1%

RIGL96.7%

Asset Turnover (TTM)

KURA0.12x

RIGL0.62x

FCF Yield (TTM)

KURA-12.5%

RIGL1.0%

Earnings Yield (TTM)

KURA-31.5%

RIGL35.5%

Dividend Yield (TTM)

KURAN/A

RIGLN/A

Rule of 40

KURA-159.3

RIGL6.6

EV/GP/RG

KURA0.09

RIGL0.13

Ticker research

View KURA research View RIGL research

Metric	KURA Kura Oncology Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$941M	$908M
Enterprise Value	$881M	$886M
Price	$10.60	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	12.18x	3.28x
EV/Sales	11.40x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	19.56x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-7.50x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	6.49x	2.61x
Revenue & Growth
Revenue (TTM)	$77M	$277M
Revenue Growth (YoY)	-7.3%	3.3%
Forward Rev Growth	106.3%	21.9%
Profitability
Gross Margin (TTM)	72.4%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-410.2%	32.4%
Net Margin (TTM)	-384.3%	116.3%
FCF Margin (TTM)	-152.1%	3.3%
Net Income (TTM)	$-297M	$322M
FCF (TTM)	$-117M	$9M
EPS (TTM)	-$3.34	$16.45
ROE (TTM)	-20718.0%	96.5%
ROA (TTM)	-4517.0%	72.3%
ROIC (TTM)	-19400.0%	84.1%
Financial Health
Cash	$70M	$61M
Debt	$10M	$39M
Net Cash/Debt	$60M	$22M
Current Ratio (TTM)	4.73x	1.94x
Quick Ratio (TTM)	4.47x	1.58x
Debt/Equity (TTM)	0.20x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.53	1.26
52W Performance	5.2%	70.7%
YTD Performance	2.6%	17.3%
% from 52W High	-23.7%	-6.0%
% from 52W Low	44.1%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.12x	0.62x
FCF Yield (TTM)	-12.5%	1.0%
Earnings Yield (TTM)	-31.5%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-159.3	6.6
EV/GP/RG	0.09	0.13
Ticker research	View KURA research	View RIGL research